I’m guessing that Platinum Equity is privy to DE

I’m guessing that Platinum Equity is privy to DECN’s position in product development and would be foolish not to take a hard look at a meaningful offer. If we only knew the contract language on PE’s purchase of JNJ Lifescan with respect to the (then pending) lawsuit. While Mr. Berman offered an estimate to Wall Street Reporter of ‘mid to high 8 figures’ for an anticipated settlement from JNJ, it sounded to me like that was a figure based on loss of sales resulting from specific actions on JNJ’s part. If you add punitive damages, I think the number could easily go into 9 digits. So the question of the lawsuit remains active at least for the time-being, and conceivably Platinum Equity might be in a position to negotiate on this point with JNJ.
Outside of all of that, I would think that all four major players would have interest in a significantly improved product. Agree that a $100M sounds reasonable in the absence of a bidding war...if that happens I’d expect that figure might be doubled (assuming appropriate IP rights are in place).
Mr. Berman also mentioned the possibility of a second suit based on the sale of LS to PE.
Anyone’s guess on where this might go, but it might offer a very pleasant return.
THEN, if none of the above happens, I’m pretty sure I’d be fine with the long awaited commercialization of DECN products that’s finally coming into view. I’d say we’re in an enviable position gentlemen.